振源胶囊联合美托洛尔对冠心病心绞痛患者心肌酶谱水平的影响

Effects of Zhenyuan capsule combined with metoprolol on the levels of myocardial enzymes in patients with angina pectoris of coronary heart disease

目的探讨振源胶囊联合美托洛尔对冠心病心绞痛患者心肌酶谱水平的影响。方法选取2019年7月至2022年7月荆州市第三人民医院收治的150例冠心病心绞痛患者作为研究对象,随机分为对照组与观察组,每组75例。对照组使用美托洛尔治疗,观察组在对照组基础上联合振源胶囊治疗。比较两组临床疗效、心肌酶谱[谷丙转氨酶(alanine aminotransferase,ALT)、谷草转氨酶(aspartate aminotransferase,AST)、肌酸激酶(creatine kinase,CK)、肌酸激酶MB亚型(creatine kinaseMB,CK-MB)、乳酸脱氢酶(lactate dehydrogenase,LDH)]水平、血液流变学指标(全血高切黏度、血浆黏度、红细胞沉降率)及不良反应发生情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗1个月后,两组ALT、AST、CK、CK-MB、LDH水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗1个月后,两组全血高切黏度、血浆黏度、红细胞沉降率均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗1个月后,两组不良反应发生率比较差异无统计学意义。结论振源胶囊联合美托洛尔治疗冠心病心绞痛疗效显著,能有效改善患者心肌酶谱水平和血液流变学指标,且药物安全性较高,值得临床应用推广。

Objective To explore the effects of Zhenyuan capsule combined with metoprolol on myocardial enzymes levels in patients with angi-na pectoris of coronary heart disease.Methods 150 patients with angina pectoris of coronary heart disease who were treated in the Third People's Hospital of Jinzhou from July 2019 to July 2022 were selected as the research subjects,and they were randomly divided into the control group and the observation group,with 75 cases in each group.The control group was treated with metoprolol while the observation group was com-bined with Zhenyuan capsule on the basis of the control group.The clinical efficacy,levels of myocardial enzymes(alanine aminotransferase[ALT],aspartate aminotransferase[AST],creatine kinase[CK],creatine kinase-MB[CK-MB],lactate dehydrogenase[LDH]),hemorheological indicators(whole blood high tangential viscosity,plasma viscosity,erythrocyte sedimentation rate)and the adverse reactions were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group,and the difference was statistically signifi-cant(P<0.05).After 1 month of treatment,the levels of ALT,AST,CK,CK-MB and LDH of the two groups were lower than those before treatment,and the observation group was lower than the control group,the differences were statistically significant(P<0.05).After 1 month of treatment,the whole blood high tangential viscosity,plasma viscosity and erythrocyte sedimentation rate of the two groups were lower than those before treatment,and the observation group was lower than the control group,the differences were statistically significant(P<0.05).There was no significant differ-ence in the incidence of adverse reactions between the two groups after 1 month of treatment.Conclusion Zhenyuan capsule combined with meto-prolol has significant efficacy on patients with angina pectoris of coronary heart disease,and can effectively improve the levels of myocardial en-zymes and hemorheology indicators,and it has high drug safety,which is worthy of clinical application and promotion.